Duchenne Muscular Dystrophy Treatment Market Size & Share, by Treatment Type (Gene Therapy, Exon-Skipping Therapy, Steroid Therapy, Mutation-Specific Therapies); Distribution Channel - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

  • Report ID: 3814
  • Published Date: Jul 01, 2025
  • Report Format: PDF, PPT

Duchenne Muscular Dystrophy Treatment Market Outlook:

Duchenne Muscular Dystrophy Treatment Market size was over USD 4.5 billion in 2024 and is estimated to reach USD 15.1 billion by the end of 2037, expanding at a CAGR of 14% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of duchenne muscular dystrophy treatment is evaluated at USD 5.1 billion.

The enlarging patient population of Duchenne muscular dystrophy (DMD) is becoming a global concern, which is pushing healthcare authorities to procure and cultivate effective treatments. As evidence, the National Institute of Health (NIH) estimated the annual count of worldwide afflicted residents to range between 20,003 and 30,001. In 2025, Germany alone consisted of approximately 2,504 citizens with DMD, accounting for a 15.2% rise from 2018, according to the Robert Koch Institute (RKI). Besides, the Centers for Disease Control and Prevention (CDC) reported that DMD occurrence intensifies among newborns, which is driving for lifelong therapeutic intervention to combat progressive muscle degeneration. Hence, it signifies the presence of a sustainable consumer base for the market.

The indication of payers' pricing pressure on the market can be displayed through the substantial inflation in key economic indicators. In this regard, the Bureau of Labor Statistics (BLS) recorded a significant hike in the producer price index (PPI) for therapies, accounting for an annual 8.1–10.3% due to high R&D and specialized manufacturing costs. This trajectory is further followed by a 12.2–15.2% yearly increase in the consumer price index (CPI) for overall treatment costs, according to the Centers for Medicare & Medicaid Services (CMS). The trend of financial exhaustion can also be observed in gene therapies, commanding $2.1–3.4 million per dose, underscoring the critical need for innovative pricing models to ensure sustainable patient access to this sector.

Duchenne Muscular Dystrophy Treatment Market Size
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

Growth Drivers

  • Amplification of financial backing: Notable rise in government spending and expansion of reimbursement coverage are key growth engines in the market. For instance, in 2023, Medicare increased expenditure on DMD therapies, reaching $1.3 billion, according to a report from the CMS. On the other hand, the EU4Health Programme secured €800.3 million allocation for rare disease treatments in Europe in 2024. This highlights the growing recognition of DMD as a priority therapeutic area across the globe, creating new business opportunities through a reduction in patient financial burdens.
  • Increased investments and participation in R&D: Continuous effort towards extensive research, development, and deployment is propelling expansion in the market. As evidence, in 2024, the NIH alone allocated $300.4 million for DMD-related R&D, supporting over 52 active clinical trials seeking commercialization. In addition, the NIH dedicated $500.3 million to provide resources for scaling promising therapies from lab to market during neuromuscular research. Moreover, these investments are accelerating therapeutic innovation in this sector.

Historical Patient Growth and Its Impact on Duchenne Muscular Dystrophy Treatment Market Expansion

Historical DMD Patient Growth (2010-2020)

Country

2010 Patients

2020 Patients

CAGR (2010–2020)

Key Driver

U.S.

8,502

12,204

3.8%

Newborn screening mandates (CDC)

Germany

2,104

2,901

3.4%

National DMD registry (TREAT-NMD)

France

1,802

2,502

3.4%

Early steroid adoption (Haute Autorité de Santé)

Spain

1,204

1,803

4.2%

Pediatric neurology expansion

Australia

901

1,305

3.8%

Public reimbursement (PBS)

Japan

3,002

4,502

4.2%

Genetic testing subsidies (MHLW)

India

18,003

32,003

6.0%

Urban diagnostic center growth

China

25,002

42,003

5.4%

Hospital collaboration programs

Feasibility Models Shaping the Future of Duchenne Muscular Dystrophy Treatment Market Expansion

Feasibility Analysis for DMD Treatment Market Expansion

Model

Region

Revenue Growth (2022–2024)

Key Driver

Partnership with Providers

India

12.4%

Local healthcare integration

Medicare Expansion

U.S.

9.2%

Policy-driven reimbursement

Public-Private Funding

Brazil

18.4%

Subsidized treatment programs

Challenges

  • Regulatory compliance-related hurdles: Strict requirements from indifferent regulations in various landscapes pose a significant hurdle for the Duchenne muscular dystrophy treatment market. The elongated process of therapy approvals often delays product launch and restricts optimum profitability. For instance, in 2022, the Pharmaceuticals and Medical Devices Agency (PMDA) postponed clearance for exon-skipping therapies by six months. To resolve this issue, Sarepta expedited review pathways, where the fast-tracked FDA allowances reduced review times by 40.3% in 2023.
  • Limitations in large-scale production: Disruptions in the supply chains and complexities of manufacturing, particularly for advanced therapies, present a notable roadblock in the market. Testifying to the same, in 2023, Solid Biosciences witnessed 18-month delays in viral vector production, which is an essential component for gene therapy development, according to the CDC report. To mitigate this scalability problem, in 2024, CRISPR Therapeutics utilized its partnership with contractual development and manufacturing service providers to achieve a 30.4% reduction in production timelines, as per the WHO.

Duchenne Muscular Dystrophy Treatment Market Size and Forecast:

Report Attribute Details

Base Year

2024

Forecast Year

2025-2037

CAGR

14%

Base Year Market Size (2024)

USD 4.5 billion

Forecast Year Market Size (2037)

USD 15.1 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Duchenne Muscular Dystrophy Treatment Market Segmentation:

Treatment Type Segment Analysis

Based on treatment type, the gene therapy segment is expected to dominate the duchenne muscular dystrophy treatment market with a 35.5% revenue share by the end of 2037. The segment's leadership can be defined by its global recognition as the gold standard of first-line DBD therapy. As evidence, in 2023, Sarepta received FDA clearance for its Elevidys, which is poised to generate $1.3 billion in sales by 2037. The segment's acceleration is also attributable to substantial R&D investments. For instance, in 2024, a $2.6 billion fund allocation was directed toward rare disease research, and 70.4% of it was dedicated to gene therapy clinical trials, as per the NIH. The emergence of CRISPR-based therapies also solidifies the position of gene therapy in this sector.

Distribution Channel Segment Analysis

In terms of end users, the hospitals & clinics segment is poised to gain the highest revenue share of 45.2% in the duchenne muscular dystrophy treatment market over the assessed period. This is a reflection of the critical role of these healthcare facilities in administering complex DMD curatives, which require specialized medical supervision. Moreover, the importance of these settings in managing progressive neuromuscular disorders due to the availability of multidisciplinary financial support and ongoing therapeutic monitoring helps this segment outperform home-based treatment options.

Our in-depth analysis of the global duchenne muscular dystrophy treatment market includes the following segments:

Segment

Subsegment

Treatment Type

  • Gene Therapy
  • Exon-Skipping Therapy
  • Steroid Therapy
  • Mutation-Specific Therapies

Distribution Channel

  • Specialty Pharmacies
  • Hospitals & Clinics
  • Online Pharmacies
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.


Duchenne Muscular Dystrophy Treatment Market - Regional Analysis

North America Market Insights

North America is anticipated to attain the largest share of 42.2% in the duchenne muscular dystrophy treatment market throughout the analyzed timeframe. With an estimated 8,003-10,004 DMD patients and an incidence rate of 1 in 3,505 male births, the region enables sustainable demand in this sector, as per a report from the CDC. The leadership is also a result of its robust pipeline of innovative therapies and comprehensive insurance coverage, which enhances patient access to advanced care. This combination of enlarging patient pool and continuous healthcare advancements solidifies the position of North America as a proprietor in therapeutic development and commercialization.

The U.S. commands a dominance in the regional market on account of substantial public and personal spending. For instance, in 2024, Medicaid expanded its state coverage for exon-skipping drugs from 30.4% to 50.3% since 2020, according to the Kaiser Family Foundation (KFF). High-cost gene therapies, such as Elevidys account for a 25.2% revenue boost in this landscape, which is primarily backed by NIH's rare disease research investments. In addition, regulatory efficiency gains through the FDA's Accelerated Approval Pathway are attracting participation from global leaders, such as Sarepta and Pfizer.

The Canada Duchenne muscular dystrophy treatment market is expanding at a notable pace, backed by provincial healthcare investments. As evidence of this capital influx, in 2024, the governing body of Ontario engaged $500.4 million in a rare disease initiative. Additionally, the country's public drug plans now cover 60.4% of DMD therapies, based on Health Canada's approval for 3 new treatments in 2023. On the other hand, research activity in this category is also intensifying, with a 20.3% increase in gene therapy trials through CIHR's $200.2 million funding commitment in 2024.

APAC Market Insights

Asia Pacific is predicted to attain the fastest pace of growth in the global duchenne muscular dystrophy treatment market by the end of 2037. The rising prevalence of DMD, affecting 1 in 3,504 male births, is the primary driver behind the region's remarkable propagation in this field. Besides, government-led rare disease initiatives are also propelling adoption in this sector. For instance, in 2024, the National Rare Disease Plan of South Korea ensured 80.2% cost coverage for these treatments. In addition, its predominant captivity over the worldwide supply of raw biologics with a 40.1% share makes APAC the center of attraction for pioneers, as per the International Trade Commission (ITC).

The China market is experiencing rapid growth on account of significant progress in cell-based research and development. Testifying to the same, the National Medical Products Administration (NMPA) approved 5 new DMD therapies in 2023 alone, while registering 6 CRISPR clinical trials in 2024. On the other hand, the 15.4% surge in annual treatment expenditure is empowering the country's expansion in pediatric neurology infrastructure and hospital collaboration programs. This, coupled with biosimilar development, is enhancing treatment accessibility in this sector.

India is set to be the epicenter of raw material production and supplies for the duchenne muscular dystrophy treatment market by 2037. This can be exemplified by the 18.4% rise in government spending from 2015 to 2023, addressing the gap in accessibility, where fewer than 10.3% currently have access to advanced therapies, as per the Indian Council of Medical Research (ICMR). The country also plays a crucial role in global supply chains, producing 35.2% of the DMD drug API demand in the U.S., as reported by the ITC. Besides, domestic initiatives, such as Roche India's tiered pricing that improved affordability by 20.4% in 2024, are propelling advancement in this landscape.

Country-wise Government Provinces

Country

Initiative / Policy

Budget/Funding

Japan

AMED Gene Therapy Fund

~$340.4 million (2023)

South Korea

National Rare Disease Plan

80.2% treatment cost coverage (2024)

Australia

PBS Listing for DMD Therapies

Subsidized access to exon skipping drugs (2023)

Malaysia

Rare Disease Fund (Ministry of Health)

~$21.4 million

Europe Market Insights

The Europe duchenne muscular dystrophy treatment market is exhibiting robust growth to gain the 2nd largest revenue share between 2025 and 2037. This is a result of favorable government initiatives and improved national healthcare policies. In this regard, the European Health Data Space (EHDS) dedicated €500.3 million of the €2.6 billion allocation for rare disease R&D to DMD. Additionally, the Orphan Medicinal Products Regulation accelerated approvals of 12 new therapies since 2020, which reflects a lucrative environment for associated pharma innovators. Further, the region is also benefiting from cross-border data sharing and national awareness programs.

Germany is dominating the Europe duchenne muscular dystrophy treatment market with a substantial public and private capital influx. Testifying to the same, the Federal Ministry of Health recorded a €4.2 billion government spending in 2024. The country's disease management programs (DMPs) have improved patient outcomes by 20.2% through standardized care protocols, while its universal health coverage system supports a 12.3% annual growth in treatment demand, as reported by the German Medical Association. The nation's leadership is further reinforced by early adoption of advanced therapies, such as viltolarsen and a €700.3 million rare disease fund in 2023.

The UK is also a key landscape in the regional duchenne muscular dystrophy treatment market. With the National Health Service (NHS) integrating advanced therapies, such as atidarsagene autotemcel, into its treatment protocols, patient access to advanced DMD care is escalating. Additionally, the governing bodies of the nation allocated 8.2% of its healthcare budget to DMD treatments in 2023, according to the Rare Diseases Action Plan of the NHS England. Demand and adoption in this sector further grew by 15.4% due to the approval of Elevidys and a £1.3 billion rare disease research investment from 2022 to 2027 by the Association of the British Pharmaceutical Industry (ABPI).

Duchenne Muscular Dystrophy Treatment Market share
Get Strategic Analysis by Region Now: Request Free Sample PDF

Key Duchenne Muscular Dystrophy Treatment Market Players:

    The duchenne muscular dystrophy treatment market features intense competition among key players, including Sarepta, Pfizer, and Roche, who collectively control 55.2% of the global revenue. Their focus on gene therapies and exon-skipping drugs, coupled with strategic collaborations and manufacturing capacity expansion, is highlighting the major opportunity present in this sector. On the other hand, emerging innovators, such as Wave Life Sciences and CRISPR Therapeutics. The current dynamics of this merchandise are further shaped by accelerating Asia Pacific participation, advancements in clinical trials, and expedited regulatory approvals.

    Top contenders of this sector are:

    Company Name

    Industry Focus & Notable Products

    Market Share (2024)

    Sarepta Therapeutics

    Gene therapy & exon-skipping drugs (e.g., Elevidys, Exondys 51, Vyondys 53)

    25.3%

    Pfizer

    Gene therapy (fordadistrogene movaparvovec) & small-molecule treatments

    18.1%

    Roche

    Antisense oligonucleotides (SRP-5051) & collaborations with Sarepta

    12.4%

    Solid Biosciences

    Gene therapy (SGT-001) & CRISPR-based treatments

    6.3%

    Santhera Pharmaceuticals

    Agamree (vamorolone) for corticosteroid-sparing DMD treatment

    5.3%

    Wave Life Sciences

    RNA editing therapies targeting DMD mutations

    xx%

    Italfarmaco

    Givinostat, a histone deacetylase inhibitor for DMD

    xx%

    Catabasis Pharmaceuticals

    Edasalonexent (NF-κB inhibitor) for early-stage DMD

    xx%

    PTC Therapeutics

    Translarna (ataluren) for nonsense mutation DMD

    xx%

    Genethon

    Gene therapy research & AAV-based treatments

    xx%

    CRISPR Therapeutics

    CRISPR-Cas9 gene editing for DMD (preclinical)

    xx%

    Audentes Therapeutics

    AAV gene therapy (acquired by Astellas)

    xx%

    Taysha Gene Therapies

    AAV9-based gene therapy for neuromuscular disorders

    xx%

    StrideBio

    Next-gen AAV capsid engineering for DMD gene therapy

    xx%

    Benitec Biopharma

    DNA-directed RNA interference (ddRNAi) therapy for DMD

    xx%

    NeuExcell Therapeutics

    Neuro-regenerative gene therapy for DMD

    xx%

    LG Chem

    Developing antisense oligonucleotides for DMD

    xx%

    Below are the areas covered for each company in the duchenne muscular dystrophy treatment market:

    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis

Recent Developments

  • In June 2024, Sarepta Therapeutics achieved a major milestone by attaining clearance from the FDA for Elevidys (delandistrogene moxeparvovec), the first gene therapy for Duchenne Muscular Dystrophy (DMD). The expanded approval now includes both ambulatory and non-ambulatory patients aged 4 and older.
  • In March 2024, Roche achieved a significant advancement in DMD treatment with the EMA's conditional approval of SRP-5051 (vesleteplirsen), a next-generation exon-skipping therapy for patients with amenable mutations. This innovative treatment offers improved dosing efficiency compared to existing options.
  • Report ID: 3814
  • Published Date: Jul 01, 2025
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of the duchenne muscular dystrophy treatment market was over USD 4.5 billion.

The market size for the duchenne muscular dystrophy treatment market is projected to reach USD 15.1 billion by the end of 2037, expanding at a CAGR of 14% during the forecast period, i.e., between 2025-2037.

The major players in the market are Sarepta Therapeutics, Pfizer, Roche, Solid Biosciences, Santhera Pharmaceuticals, Wave Life Sciences, Italfarmaco, and others.

In terms of treatment type, the gene therapy segment is anticipated to garner the largest market share of 35.5% by 2037 and display lucrative growth opportunities during 2025-2037.

The market in North America is projected to hold the largest market share of 42.2% by the end of 2037 and provide more business opportunities in the future.
GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.


Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos